Prolia (denosumab) is an important treatment option for patients at increased risk of osteoporotic fractures. Because its effects on bone remodeling are closely linked to the timing of administration, correct dosing, appropriate patient selection, calcium and vitamin D management, and regular monitoring are essential components of safe treatment. Unlike bisphosphonates, Prolia is a monoclonal antibody […]
